Nurix To Report New Data From Ongoing Trial Of Bexobrutideg In B-Cell Malignancies

Nurix Therapeutics (NRIX) will present updated Phase 1 data on bexobrutideg (NX-5948), an oral BTK degrader, at the EHA2025 congress, highlighting rapid and durable clinical responses in relapsed/refractory CLL and Waldenström macroglobulinemia patients; the company plans to initiate pivotal studies for NX-5948 in CLL and advance other degrader programs with Gilead and Sanofi, driving NRIX stock up 2.92% to $12.86.

Analysis

Nurix Therapeutics is set to unveil new clinical data for its investigational oral Bruton's tyrosine kinase (BTK) degrader, bexobrutideg (NX-5948), at the European Hematology Association Congress (EHA2025) in June, an event that has contributed to a 2.92% rise in NRIX stock to $12.86. The ongoing Phase 1a/b study of bexobrutideg in patients with relapsed or refractory B cell malignancies, including chronic lymphocytic leukemia (CLL) and Waldenström macroglobulinemia (WM), has already demonstrated rapid, durable clinical responses and a tolerable safety profile. Nurix plans to present updated Phase 1a data in CLL and clinical activity/safety data in WM at EHA2025. Strategically, the company intends to advance NX-5948 into pivotal studies for CLL in 2025, alongside expanding its application into other cancers and inflammatory diseases. Further pipeline developments include driving NX-2127 and NX-1607 to proof-of-concept, advancing an IRAK4 degrader program with Gilead into clinical development, nominating a STAT6 degrader candidate with Sanofi, and selecting a wholly owned degrader candidate for IND-enabling studies, indicating a robust outlook underpinned by multiple programs and collaborations.

Key Decisions for Investors

• Investors should closely monitor the detailed bexobrutideg data presented at EHA2025, as positive results could serve as a significant near-term catalyst for NRIX stock.
• Consider the company's broader strategic plan for 2025, including the initiation of pivotal studies for NX-5948 and progress in partnered programs with Gilead and Sanofi, which could unlock further value.
• Evaluate the risk-reward profile in light of the upcoming clinical data release and the inherent uncertainties associated with drug development, adjusting positions based on the strength of the EHA2025 results and subsequent pipeline execution.